Nilotinib Eg

Nilotinib, the active ingredient in Nilotinib Eg, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in specific leukemias.

- Chronic myeloid leukemia (CML): Reduces disease progression and improves survival across chronic, accelerated, and blast phases. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): Provides a molecularly directed option to achieve remission. - BCR‑ABL positive leukemias: Delivers selective inhibition of the oncogenic kinase driving malignant cell proliferation.

Common Side Effects: - Nausea - Diarrhea - Rash - Fatigue

Serious or Rare Side Effects: - QT interval prolongation - Pancreatitis - Severe hepatic toxicity

Nilotinib requires careful monitoring due to its potent pharmacologic profile. - Cardiac monitoring: Obtain baseline ECG and periodically assess QT interval. - Hepatic function: Check liver enzymes before initiation and during treatment. - Electrolyte balance: Correct hypokalemia and hypomagnesemia to mitigate cardiac risk. - Drug interactions: Review concomitant CYP3A4‑modulating agents. - Pregnancy: Category D; avoid use in pregnancy unless benefits outweigh risks. - Store at ambient temperature: Keep below 25°C in the original pack, protect from moisture.

Nilotinib interacts with several medicines that affect its absorption or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease nilotinib exposure. - Antacids containing aluminum or magnesium: Reduce oral absorption. - QT‑prolonging agents (e.g., amiodarone, sotalol): Heighten risk of arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase plasma levels. - Warfarin: Potentially enhances anticoagulant effect; monitor INR.